Therapeutics of neurotransmitters in Alzheimer's disease

R Kandimalla, PH Reddy - Journal of Alzheimer's Disease, 2017 - content.iospress.com
Alzheimer's disease (AD) is a progressive neurodegenerative disease, characterized by the
loss of memory, multiple cognitive impairments and changes in the personality and …

Neurotransmitters in prevention and treatment of Alzheimer's disease

Z Yang, Y Zou, L Wang - International Journal of Molecular Sciences, 2023 - mdpi.com
Alzheimer's disease (AD) is the most frequent cause of cognitive impairment in middle-aged
and older populations. There is a lack of drugs that demonstrate significant efficacy in AD, so …

Pathophysiological aspects and therapeutic armamentarium of Alzheimer's disease: recent trends and future development

BP Dave, YB Shah, KG Maheshwari… - Cellular and Molecular …, 2023 - Springer
Alzheimer's disease (AD) is the primary cause of dementia and is characterized by the death
of brain cells due to the accumulation of insoluble amyloid plaques, hyperphosphorylation of …

Insights into the pathophysiology of Alzheimer's disease and potential therapeutic targets: A current perspective

K Rajah Kumaran, S Yunusa, E Perimal… - Journal of …, 2023 - content.iospress.com
The aging population increases steadily because of a healthy lifestyle and medical
advancements in healthcare. However, Alzheimer's disease (AD) is becoming more …

The neurobiology and pharmacotherapy of Alzheimer's disease

O Felician, TA Sandson - The Journal of neuropsychiatry …, 1999 - Am Neuropsych Assoc
Alzheimer's disease (AD), the most common cause of dementia, has become a major public
health concern as our population ages. In recent years, AD has attracted the attention of a …

Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau

Y Hong-Qi, S Zhi-Kun, C Sheng-Di - Translational neurodegeneration, 2012 - Springer
Alzheimer's disease (AD) is a neurodegenerative disorder that impairs mainly the memory
and cognitive function in elderly. Extracellular beta amyloid deposition and intracellular tau …

Advances in developing novel therapeutic strategies for Alzheimer's disease

J Cao, J Hou, J Ping, D Cai - Molecular neurodegeneration, 2018 - Springer
Abstract Alzheimer's Disease (AD), the most prevalent neurodegenerative disease of aging,
affects one in eight older Americans. Nearly all drug treatments tested for AD today have …

Therapeutics of Alzheimer's disease: Past, present and future

R Anand, KD Gill, AA Mahdi - Neuropharmacology, 2014 - Elsevier
Alzheimer's disease (AD) is the most common cause of dementia worldwide. The etiology is
multifactorial, and pathophysiology of the disease is complex. Data indicate an exponential …

Novel therapeutic approaches for Alzheimer's disease: an updated review

TW Yu, HY Lane, CH Lin - International journal of molecular sciences, 2021 - mdpi.com
Alzheimer's disease (AD) is a progressive neurodegenerative disease and accounts for
most cases of dementia. The prevalence of AD has increased in the current rapidly aging …

[HTML][HTML] Recent advances in the neurobiology and neuropharmacology of Alzheimer's disease

K Kumar, A Kumar, RM Keegan… - Biomedicine & …, 2018 - Elsevier
Alzheimer's disease (AD) is an age-related neurodegenerative disorder characterized by
progressive deterioration of cognitive functions. The pathological hallmarks are extracellular …